SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

Share Price is delayed by 15 minutes
Get Live Data
0.53    -0.002 (-0.38%)
Bid:
0.51
Ask:
0.528
Spread: 0.018 (3.529%)
Market Cap: $308.10m
IDHC Live PriceLast checked at - London Stock Exchange

Intraday Int Diag Hld Share Chart

Final dividend clarification

9 Jul 2021 16:16

RNS Number : 8200E
Integrated Diagnostics Holdings PLC
09 July 2021
 

Integrated Diagnostics Holdings plc

(the "Company")

 

Final dividend clarification

 

9 July 2021

 

(Cairo and London) - In reference to resolution 10 approved by shareholders at the Annual General Meeting (AGM) of the Company held on 30 June 2021, the Company notes that the final dividend to be distributed on 29 July 2021 amounts to US$ 29.1 million in aggregate for the year ended 31 December 2020 (as previously stated in the FY2020 and 1Q2021 results announcements issued on 19 May 2021 and 2 June 2021, respectively). This equates to a dividend of US$ 0.0485 per share (due to an administrative oversight the figure was rounded to three rather than four decimal places to US$ 0.049 in the AGM Circular and Summary of Proxy Voting documents issued on 7 June 2021 and 30 June 2021, respectively), and is 4% higher than the US$ 28.0 million in aggregate distributed in the previous financial year.

 

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 483 branches as of 31 March 2021, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com.

 

The person responsible for arranging the release of this announcement is Nancy Fahmy, Investor Relations Director at IDH.

 

Contact

Nancy Fahmy

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | nancy.fahmy@idhcorp.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVUPUCGMUPGGAB
Date   Source Headline
20th May 20262:05 pmRNSReplacement - 1st Quarter Results
20th May 20267:00 amRNS1st Quarter Results
19th May 20265:09 pmRNSResult of AGM
30th Apr 202612:39 pmRNSReplacement - Holding(s) in Company
23rd Apr 20261:06 pmRNSAnnual Financial Report & Notice of AGM
17th Apr 20267:00 amRNSFinal Results
8th Apr 20265:50 pmRNSHolding(s) in Company
8th Apr 20265:49 pmRNSHolding(s) in Company
13th Nov 20257:00 amRNS3rd Quarter Results
7th Nov 20257:00 amRNSNotice of Results
2nd Sep 20257:00 amRNSHalf-year Report
29th Aug 202511:55 amRNSNotice of Results
20th Jun 20257:00 amRNSIDH Strengthens Egyptian Radiology portfolio
28th May 20257:00 amRNS1st Quarter Results
27th May 20255:00 pmRNSResult of AGM
22nd May 20257:00 amRNSNotice of Results
24th Apr 20253:30 pmRNSAnnual Financial Report & Notice of AGM
17th Apr 20257:00 amRNSFinal Results
10th Apr 20254:41 pmRNSNotice of Results
9th Dec 202410:59 amRNSIDH INCREASES STAKE IN BIOLAB KSA
14th Nov 20247:00 amRNS3rd Quarter Results
11th Nov 202411:29 amRNSNotice of Results
8th Oct 20245:21 pmRNSCancellation of Treasury Shares
1st Oct 20249:00 amRNSTotal Voting Rights
18th Sep 20244:14 pmRNSCompletion of Treasury Shares Removal Process
6th Sep 20247:00 amRNSUpdate on Treasury Shares Removal Process
5th Sep 20247:00 amRNSCompletion of EGX Delisting
28th Aug 20247:00 amRNSHalf-year Report
27th Aug 20247:00 amRNSEGX Delisting – buyback under EGX's OPR
23rd Aug 20241:30 pmRNSNotice of Results
13th Aug 20247:00 amRNSEGX Delisting – timeline under EGX's OPR
18th Jul 20243:45 pmRNSResults of Extraordinary General Meeting
1st Jul 20243:40 pmRNSPublication of Circular and Notice of EGM
27th Jun 20247:00 amRNSIDH's proposed revised Delisting Buyback Price
12th Jun 20243:35 pmRNSResults of Extraordinary General Meeting
30th May 20247:00 amRNS1ST QUARTER RESULTS
29th May 20243:44 pmRNSResult of AGM
28th May 202410:42 amRNSNotice of Results
24th May 20244:16 pmRNSPublication of Circular and Notice of EGM
16th May 20247:00 amRNSIDH proposing to delist its shares from the EGX
30th Apr 20242:13 pmRNSNotice of AGM
4th Apr 20241:55 pmRNSAnnual Financial Report
28th Mar 20247:00 amRNSFinal Results
26th Mar 20249:15 amRNSNotice of Results
18th Jan 20244:03 pmRNSIDH appoints Group CFO, VP and Board Member
16th Nov 20237:00 amRNS3rd Quarter Results
25th Oct 20237:00 amRNSIDH CEO increases stake in the Company
17th Oct 20231:56 pmRNSDirector/PDMR Shareholding
16th Oct 202312:26 pmRNSDirector/PDMR Shareholding
13th Oct 20232:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.